Novasep to supply API to Celladon; FDA OKs Kemwell plant; Recipharm and Adroit work together;

> Novasep and Celladon have an API supply agreement for Novasep to manufacture Celladon's genetically targeted enzyme replacement therapy MYDICAR. Release

> Horizon Discovery Group has received £652,000 from the U.K.'s Advanced Manufacturing Supply Chain Initiative to expand bioproduction research into how to accelerate the development of novel and improved Chinese hamster ovary cell lines. Report

> Bangalore, India-based CDMO Kemwell says it has successfully passed an FDA inspection tied to an ANDA submitted by a client. Release

> CDMO Recipharm will begin using solid state characterization services from Adroit Science. Release

And Finally... A compounders group is discouraging members from providing drugs for state executions. Story

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.